Weifa has in-licensed a patented fixed-combination product line within pain management from AFT Pharmaceuticals (AFT) in New Zealand. The agreement gives rights to commercialize the products in the entire Nordic region (Norway, Sweden, Denmark, Finland and Iceland). The product line consists of a patented fixed ratio of ibuprofen and paracetamol, and covers tablet, sachet and oral liquid formulations. The products are indicated for acute pain and fever conditions, and will be marketed under Weifa's own brand name.